Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
Year: 2010
Type: article
Study design: Clinical Trial
Source: Leukemia
DOI: 10.1038/leu.2010.110
Institutions: The University of Texas at San Antonio Health Science Center, St. Eugenio Hospital, University of Bologna, Catholic University of Korea, City Of Hope National Medical Center, City of Hope, Rutgers, The State University of New Jersey, Hackensack University Medical Center, Singapore General Hospital, Vanderbilt University, Vanderbilt University Medical Center, Medical University of Silesia, Klinikum Magdeburg, University Hospital Magdeburg, Otto-von-Guericke-Universität Magdeburg, Université de Lille, Centre Hospitalier Universitaire de Lille, Goethe University Frankfurt, Hammersmith Hospital, Imperial College London, Heidelberg University, Medizinische Fakultät Mannheim, Novartis (United States), University of Chicago, Institut Bergonié, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: National Cancer Institute
OpenAlex ID: W2039531591